The EU Council has published a note containing a four-column table comparing the European Commission's original proposal for the Critical Medicines Act with the amended positions of the European Parliament and the Council. The document, dated 2 May 2026, aims to strengthen the security of supply and availability of critical medicines in the EU by addressing shortages, reducing dependencies on third-country suppliers, and boosting EU manufacturing capacity through incentives and better coordination.
Document Details
The note is a procedural document from the Council, presenting the legislative positions of the three EU institutions in a comparative format. It focuses on amendments to the recitals of the proposed regulation, which would amend Regulation (EU) 2024/795. The document does not represent a final agreement but serves as a basis for further negotiations.
Policy Orientations and Trade-offs
The proposed Critical Medicines Act seeks to reduce the EU's reliance on non-EU suppliers for critical medicines, a vulnerability exposed during the COVID-19 pandemic. The Commission's original proposal includes incentives for EU manufacturing, such as tax breaks and streamlined approval processes. The Parliament has pushed for stronger transparency requirements and binding targets for domestic production, while the Council has emphasized flexibility for member states and cost control. The trade-off lies between ensuring supply security and maintaining competitive pricing: stricter localization requirements could raise costs for healthcare systems and consumers, but may reduce the risk of shortages.
Impact on Stakeholders
- EU pharmaceutical manufacturers: Stand to benefit from incentives and increased demand for locally produced medicines, but may face higher compliance costs and competition from new market entrants. - National health authorities: Will need to coordinate procurement and stockpiling, potentially increasing administrative burdens but improving crisis preparedness. - EU consumers/patients: Could experience more reliable access to critical medicines, but possibly at higher prices if production costs rise. - Third-country suppliers: May lose market share in the EU, impacting their revenues and potentially leading to trade tensions.
Institutional Follow-up
The four-column table will inform the next round of trilogue negotiations between the Commission, Parliament, and Council. The Parliament's Committee on the Environment, Public Health and Food Safety (ENVI) is expected to adopt its negotiating mandate soon, while the Council will refine its position. A final agreement is anticipated by late 2026.
← Atlas › News › Health & Lifestyle